Clinical trial
Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants…
NCT03737110 · Kiniksa Pharmaceuticals (UK), Ltd., Industry · Completed
Key facts
| NCT number | NCT03737110 |
|---|---|
| Title | Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis |
| Official title | Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study With Open-label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis |
| Acronym | RHAPSODY |
| Lead sponsor | Kiniksa Pharmaceuticals (UK), Ltd., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Recurrent Pericarditis |
| Intervention type | Drug |
| Interventions | Rilonacept, Placebo |
| Enrollment | 86 |
| Start date | Jan 7, 2019 |
| Primary completion | May 29, 2020 |
| Completion | Jun 30, 2022 |
| First posted | Nov 9, 2018 |
| Last update posted | Sep 6, 2023 |
| Countries | Australia, Israel, Italy, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: